SOURCE: Active Biotech

May 04, 2007 02:37 ET

Active Biotech Interim Report Jan-March 2007

LUND, SWEDEN -- (MARKET WIRE) -- May 4, 2007 -- * Laquinimod - Phase II data presented at the American Academy of Neurology (AAN) conference in Boston

* ANYARA - Phase II/III studies proceeding according to plan

* TASQ - New positive clinical results reported for prostate cancer project

* 57-57 - Clinical Phase I study proceeding according to plan

* I-3D - Initial clinical micro-dosing study concluded

* RhuDex® - Clinical Phase IIa studies initiated

* Net sales SEK 2.6 M (1.7)

* Operating loss SEK 52.5 M (loss: 43.0)

* Loss after tax SEK 55.8 M (loss: 47.4)

* Loss per share for the period amounted to SEK 1.27 (loss: 1.19)

For further information, please contact:

Sven Andréasson                      Cecilia Hofvander
President and CEO                    Manager Corporate Communication
Tel: +46 (0)46-19 20 49              Tel: +46 (0)46-19 11 22

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724
SE-220 07 Lund
Sweden
Tel. +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50

This report is also available at www.activebiotech.com

Interim Report Jan-March 2007: http://hugin.info/1002/R/1124090/207930.pdf

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information